In March, the pharmaceutical company Solaxa has announced plans to conduct a phase 3 clinical trial of their drug SLX-100 (repurposed 4-Aminopyridine) for Spinocerebellar ataxia 27b (SCA27b). The trial will be based in the US, but additional trial sites are to be announced later this year.
Read more here.
Read about 4-Aminopyridine here.